NCT05238558View on ClinicalTrials.gov

Safety and Immune Response to FMPV-1

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

January 31, 2022

Primary Completion Date

October 31, 2022

Study Completion Date

June 30, 2023

Conditions
Colorectal Cancer
Interventions
BIOLOGICAL

FMPV-1

Intradermal administration

BIOLOGICAL

GM-CSF (as adjuvant)

Intradermal administration

Trial Locations (1)

NG11 6JS

Quotient Sciences, Nottingham

Sponsors
All Listed Sponsors
collaborator

Quotient Sciences

INDUSTRY

lead

Hubro Therapeutics AS

INDUSTRY

NCT05238558 - Safety and Immune Response to FMPV-1 | Biotech Hunter | Biotech Hunter